Adage Capital Partners GP L.L.C. Sells 22,944 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Adage Capital Partners GP L.L.C. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 93,056 shares of the biopharmaceutical company's stock after selling 22,944 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.07% of Alnylam Pharmaceuticals worth $21,897,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC grew its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares during the period. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $33,000. OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Versant Capital Management Inc lifted its stake in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 83 shares during the period. Finally, IFP Advisors Inc boosted its holdings in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CMO Pushkal Garg sold 1,561 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the transaction, the chief marketing officer now directly owns 13,537 shares of the company's stock, valued at approximately $3,454,236.29. The trade was a 10.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock worth $1,875,627 over the last three months. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 price objective on the stock. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. Citigroup raised their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday. Finally, Bank of America raised their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $316.63.

Alnylam Pharmaceuticals Stock Up 1.2 %

Alnylam Pharmaceuticals stock traded up $3.04 during midday trading on Friday, reaching $258.17. The stock had a trading volume of 219,154 shares, compared to its average volume of 882,232. The company has a fifty day moving average price of $247.93 and a two-hundred day moving average price of $255.50. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $33.58 billion, a P/E ratio of -118.97 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the company posted ($0.16) EPS. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.